James Loerop - 01 Feb 2026 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Business Officer
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Feb 2026
Net transactions value: -$39,630
Form type: 4
Filing time: 03 Feb 2026, 17:34:33 UTC
Previous filing: 05 Jan 2026
Next filing: 06 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Loerop James	Chief Business Officer	C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE	/s/ Matthew Rothman, Attorney-in-Fact	03 Feb 2026	0001781549

This filing has been restated, see here for the amended filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Tax liability	$39,630	-15,980	-13%	$2.48	102,773	01 Feb 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F2	This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported. This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings.